Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CHKA | P35790 | 4/20 | 0.38 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19361138 | 0.93 | SIGMAR1 (0.56) | SIGMAR1HSD17B10TSHRALDH1A1KMT2A | |
| SCHEMBL14312080 | 0.93 | SIGMAR1 (0.56) | SIGMAR1HSD17B10TSHRALDH1A1KMT2A | |
| SCHEMBL16855794 | 0.93 | SIGMAR1 (0.56) | SIGMAR1HSD17B10TSHRALDH1A1KMT2A | |
| SCHEMBL14728651 | 0.93 | SIGMAR1 (0.56) | SIGMAR1HSD17B10TSHRALDH1A1KMT2A | |
| SCHEMBL12605217 | 0.93 | SIGMAR1 (0.56) | SIGMAR1HSD17B10TSHRALDH1A1KMT2A | |
| SCHEMBL18121357 | 0.91 | HSD17B10 (0.47) | SIGMAR1HSD17B10TSHRALDH1A1KMT2A | |
| SCHEMBL10317239 | 0.89 | HSD17B10 (0.48) | SIGMAR1HSD17B10ALDH1A1 | |
| SCHEMBL9119001 | 0.89 | HSD17B10 (0.48) | SIGMAR1HSD17B10ALDH1A1 | |
| SCHEMBL22661894 | 0.89 | HSD17B10 (0.48) | SIGMAR1HSD17B10ALDH1A1 | |
| SCHEMBL12018111 | 0.89 | HSD17B10 (0.48) | SIGMAR1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20040067201-A1 | Substituted 1,4,8,11-tetraazabicyclo(6.6.2)hexadecane manganese (II) complexes; imaging vascular or nephric tissue | THE PROCTER & GAMBLE COMPANY | 2004-04-08 | — | — | US | disclosed |
| US-20020119101-A1 | MRI image enhancement compositions | THE PROCTER & GAMBLE COMPANY | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | SIGMAR1 1699/4885HSD17B10 1624/4885TSHR 1149/4885 |
| US-20040067201-A1 | Substituted 1,4,8,11-tetraazabicyclo(6.6.2)hexadecane manganese (II) complexes; imaging vascular or nephric tissue | PKD1, SLC10A1, TFRC | SIGMAR1 1053/4885HSD17B10 2268/4885TSHR 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.